Respiratory syncytial virus infection in adults

Antiviral Therapy

Volumn 12, Issue 4 B, 2007, Pages 659-670

  Murata, Yoshihiko ^a   Falsey, Ann R ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BMS 433771; CJ 4 16 4; CL 387626; CROFELEMER; DEXTRAN SULPHATE; HEPARIN; JNJ 2408068; MOTAVIZUMAB; PALIVIZUMAB; PM 1001; PM 1002; PM 520; POLYOXOMETALIC ACID DERIVATIVE; R 170591; RFI 641; RIBAVIRIN; UNCLASSIFIED DRUG; YM 53403;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC TEST; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION RISK; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; SYMPTOMATOLOGY; UNITED STATES; VIRUS INFECTION; VIRUS PATHOGENESIS;

ADULT; ANTIVIRAL AGENTS; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS;

EID: 34547774521     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). Am J Hyg 1957; 66:281-290.
2. Englund JA, Sullivan CJ, Jordan MC, Dehner LP, Vercellotti GM, Balfour HH. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 1988; 109:203-208.
3. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749-1759.
4. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the united states. J Am Med Assoc 2003; 289:179-186.
5. Collins P. The molecular biology of human respiratory syncytial viruses (RSV) of the genus pneumovirus. In: The Paramyxoviruses. Kingsbury DW (editor). New York: Springer-Verlag,; 1991. pp. 103-162.
6. Johnson PR, Spriggs MK, Olmsted RA, Collins PL. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: Extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A 1987; 84:5625-5629.
7. Walsh EE, Hall CB, Briselli M, Brandriss MW, Schlesinger JJ. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J Infect Dis 1987; 155:1198-1204.
8. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clinic Microbiol Rev 2000; 13:371-384.
9. Mullooly JP, Bridges CB, Thompson WW, et al. Influenza and RSV-associated hospitalizations. Vaccine 2007; 25:846-855.
10. Griffin M, Coffey CS, Neuzil KM, Mitchel EF, Wright PF, Edwards K. Winter viruses: Influenza and respiratory syncytial virus-related morbidity in chronic lung disease. Arch Intern Med 2003; 162:1229-1236.
11. Garvie DG, Gray J. Outbreak of respiratory syncytial virus infection in the elderly. Br Med J 1980; 281:1253-1254.
12. Center for Disease Control. Epidemiologic notes and reports: Respiratory syncytial virus - missouri. MMWR 1977; 26:351.
13. Falsey AR, McCann RM, Hall WJ, et al. Acute respiratory tract infection in daycare centers for older persons. J Am Geriatr Soc 1995; 43:30-36.
14. Nicholson KG, Kent J, Hammersley V, Esperanza C. Acute viral infections of upper respiratory tract in elderly people living in the community; comparative, prospective, population based study of disease burden. Br Med J 1997; 315:1060-1064.
15. Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: An observational study. Lancet 2001; 358:1410-1416.
16. Dowell SF, Anderson LJ, Gary HEJ, et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis 1996; 174:456-462.
17. Walsh EE, Falsey AR, Hennessey PA. Respiratory syncytial virus and other infections in persons with chronic cardiopulmonary disease. Am J Respir Crit Care Med 1999; 160:791-795.
18. Sommerville RG. Respiratory syncytial virus in acute exacerbations of chronic bronchitis. Lancet 1963; 11:1247-1248.
19. Carilli A, Gohd R, Gordon W. A virologic study of chronic bronchitis. N Engl J Med 1964; 170:123-127.
20. Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: A case-control study. Thorax 2003; 58:37-42.
21. Seemungal T, Harper-Owen R, Angshu B, et al. Respiratory viruses, symptoms, and inflammatory markers in acute axacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1618-1623.
22. Rohde G, Borg I, Arinir U, et al. The role of RSV in respiratory infections in adults. 101st International Meeting of the American Thoracic Society. 23 May 2005, San Diego, USA. Poster J77.
23. Borg I, Rohde G, Loseke S, et al. Evaluation of quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases. Eur Resp J 2003; 21:944-951.
24. Wilkinson TMA, Donaldson GC, Johnston SL, Openshaw PJM, Wedzicha JA. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:871-876.
25. Falsey AR, Formica MA, Hennessey PA, Criddle M, Sullender WM, Walsh EE. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 173:639-643.
26. Falsey AR, Treanor JJ, Betts RF, Walsh EE. Viral respiratory infections in the institutionalized elderly: Clinical and epidemiologic findings. J Am Geriatr Soc 1992; 40:115-119.
27. Walsh EE, Peterson DR, Falsey AR. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly. J Infect Dis 2007; 195:1046-1051.
28. Wald TG, Miller BA, Shult P, Drinka P, Langer L, Gravenstein S. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons? J Am Geriatr Soc 1995; 43:170-174.
29. Mathur U, Bentley DW, Hall CB. Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill. Ann Intern Med 1980; 93:49-52.
30. Sorvillo FJ, Huie SF, Strassburg MA, Butsumyo A, Shandera WX, Fannin SL. An outbreak of respiratory syncytial virus pneumonia in a nursing home for the elderly. J Infect 1984; 9:252-256.
31. Simpson JL, Moric I, Wark P, Johnston L, Gibson PG. Use of induced sputum for the diagnosis of influenza and infections in asthma: A comparison of diagnostic methods. J Clin Virol 2003; 26:339-346.
32. Englund JA, Piedra P, Jewell A, Baxter BB, Whimbey E, Patel K. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol 1996; 34:1649-1653.
33. Hall WJ, Hall CB, Speers DM. Respiratory syncytial virus infection in adults: Clinical, virologic, and serial pulmonary function studies. Ann Intern Med 1978; 88:203-205.
34. Falsey AR, McCann RM, Hall WJ, Criddle MM. Evaluation of four methods for the diagnosis of respiratory syncytial virus infection in older adults. J Am Geriatr Soc 1996; 44:71-73.
35. Kellogg JA. Culture vs direct antigen assays for detection of microbial pathogens from lower respiratory tract specimens suspected of containing the respiratory syncytial virus. Arch Pathol Lab Med 1991; 115:451-458.
36. Ohm-Smith MJ, Nassos PS, Haller BL. Evaluation of the binax NOW, BD directogen, and BD directogen EZ assays for detection of respiratory syncytial virus. J Clin Microbiol 2004; 42:2996-2999.
37. Casiano-Colon AE, Hulbert BB, Mayer TK, Walsh EE, Falsey AR. Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial infection in adults. J Clin Virol 2003; 28:169-174.
38. Borek AP, Clemens SH, Gaskins VK, Aird DZ, Valsamakis A. Respiratory syncytial virus detection by remel xpect, binax NOW RSV, direct immunofluorescent staining, and tissue culture. J Clin Microbiol 2006; 44:1105-1107.
39. Falsey AR, Formica MA, Walsh EE. Diagnosis of respiratory syncytial virus infection: Comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol 2002; 40:817-820.
40. Fan J, Henrickson KJ, Savatski LL. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization (hexaplex) assay. Clin Infect Dis 1998; 26:1-6.
41. Freymuth, Vabret A, Gourain S, et al. Epidemiology and diagnosis of respiratory syncytial virus in adults. Rev Mal Respir 2000; 21:13-14.
42. Falsey AR, Formica MA, Treanor JJ, Walsh EE. Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding. J Clin Microbiol 2003; 41:4160-4165.
43. Moore C, Valappil M, Corden S, Westmoreland D. Enhanced clinical utility or the NucliSens EasyQ RSV A+B assay for tapid detection of respiratory syncytial virus in clinical samples. Eur J Clin Microbiol Infect Dis 2006; 25:167-174.
44. Erdman D, Anderson LJ. Monoclonal antibody-based capture enzyme immunoassays for specific serum immunoglobulin G (IgG), IgA, and IgM antibodies to respiratory syncytial virus. J Clin Microbiol 1990; 28:2744-2749.
45. Vikerfors T, Grandien M, Johansson M, Pettersson CA. Detection of an immunoglobulin M response in the elderly for early diagnosis of respiratory syncytial virus infection. J Clin Microbiol 1988; 26:808-811.
46. Blanco JCG, Boukhvalova MS, Hemming P, Ottolini M, Prince GA. Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection. Expert Rev Antiinfective Therapy 2005; 3:945-955.
47. Jafri HS. Treatment of respiratory syncytial virus: Antiviral therapies. Pediatr Infect Dis J 2003; 22 Suppl 2:S89,92; discussion S92-3.
48. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983; 308:1443-1447.
49. Rodriguez WJ, Arrobio J, Fink R, Kim HW, Milburn C. Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis, ribavirin study group. Arch Pediatr Adolesc Med 1999; 153:469-474.
50. Liss HP, Bernstein J. Ribavirin aerosol in the elderly. Chest 1988; 93:1239-1241.
51. Feldman RJ, Fidalgo HC, John JFJ. Respiratory syncytial virus in a cardiac surgery intensive care unit. J Thor Cardiovascular Surg 1994; 108:1152.
52. Englund JA, Piedra P, Jefferson LS, Wilson SZ, Taber LH, Gilbert BE. High-dose, short duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr 1990; 117:313-320.
53. Wyde PR, Laquerre S, Chetty SN, Gilbert BE, Nitz TJ, Pevear DC. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res 2005; 68:18-26.
54. Wyde PR, Chetty SN, Timmerman P, Gilbert BE, Andries K. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res 2003; 60:221-231.
55. Wyde PR, Moore-Poveda DK, O'Hara B, Ding WD, Mitsner B, Gilbert BE. CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antiviral Res 1998; 38:31-42.
56. Cianci C, Genovesi EV, Lamb L, et al. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother 2004; 48:2448-2454.
57. Cianci C, Yu KL, Combrink K, et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 2004; 48:413-422.
58. Huntley CC, Weiss WJ, Gazumyan A, et al. RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother 2002; 46:841-847.
59. Andries K, Moeremans M, Gevers T, et al. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antivir Res 2003; 60:209-219.
60. Walsh EE, Schlesinger JJ, Brandriss M. Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus. J Gen Virol 1986; 65:761-767.
61. Heminway BR, Yu Y, Perrine KG, et al. Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion. Virology 1994; 200:801-805.
62. Karron R, Buonagurio D, Georgiu A, et al. Respiratory syncyntial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A 1997; 94:13961-13966.
63. Feldman SA, Hendry RM, Beeler JA. Identification of a linear heparin binding domain for human respiratory syncytical virus attachment glycoprotein G. J Virol 1999; 73:6610-6617.
64. Hosoya M, Balzarini J, Shigeta S, De Clercq E. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins. Antimicrob Agents Chemother 1991; 35:2515-2520.
65. Budge PJ, Graham BS. Inhibition of respiratory syncytial virus by RhoA-derived peptides: Implications for the development of improved antiviral agents targeting heparin-binding viruses. J Antimicrob Chemother 2004; 54:299-302.
66. Barnard DL, Hill CL, Gage T, et al. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Antiviral Res 1997; 34:27-37.
67. Shigeta S, Mori S, Kodama E, Kodama J, Takahashi K, Yamase T. Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates. Antiviral Res 2003; 58:265-271.
68. Liuzzi M, Mason SW, Carrier M, et al. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. J Virol 2005; 79:13105-13115.
69. Sudo K, Miyazaki Y, Kojima N, et al. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res 2005; 65:125-131.
70. Leaman DW. 2-5A antisense treatment of respiratory syncytial virus. Curr Opin Pharmacol 2005; 5:502-507.
71. Maggon K, Barik S. New drugs and treatment for respiratory syncytial virus. Rev Med Virol 2004; 14:149-168.
72. Xu Z, Kuang M, Okicki JR, Cramer H, Chaudhary N. Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin. Antiviral Res 2004; 61:195-206.
73. Ahlquist P. RNA-dependent RNA polymerases, viruses, and RNA silencing. Science 2002; 296:1270-1273.
74. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11:50-55.
75. Zhang W, Yang H, Kong X, et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 2005; 11:56-62.
76. Gilbert BE, Wyde PR, Wilson SZ, Meyerson LR. SP-303 small-particle aerosol treatment of influenza A virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res 1993; 21:37-45.
77. Ojwang JO, Wang YH, Wyde PR, et al. A novel inhibitor of respiratory syncytial virus isolated from ethnobotanicals. Antiviral Res 2005; 68:163-172.
78. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993; 329:1524-1530.
79. Groothuis JR, Simoes EAF, Hemming VG, Respiratory syncytial virus immune gobulin study group. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics 1995; 95:463-467.
80. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-537.
81. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001; 184:350-354.
82. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunogloblin. Bone Marrow Transplant 2000; 25:751-755.
83. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly adults. J Infect Dis 2004; 189:233-238.
84. Walsh EE, Falsey AR. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. J Med Virol 2004; 73:295-299.
85. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 2004; 190:373-378.
86. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alumprecipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:435-448.
87. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-434.
88. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969; 89:449-463.
89. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 1996; 14:1214-1218.
90. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997; 15:1130-1132.
91. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003; 21:3465-3467.
92. Power UF, Nguyen TN, Rietveld E, et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 2001; 184:1456-1460.
93. Karron RA, Wright PF, Crowe JE, et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997; 176:1428-1436.
94. Juhasz K, Whitehead SS, Boulanger CA, Firestone CY, Collins PL, Murphy BR. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine 1999; 17:1416-1424.
95. Whitehead SS, Firestone CY, Karron RA, et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 1999; 73:871-877.
96. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000 182:1331-1342.
97. Gonzalez IM, Karron RA, Eichelberger M, et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 2000 18:1763-1772.
98. Graham BS, Rutigliano JA, Johnson TR. Respiratory syncytial virus immunobiology and pathogenesis. Virology 2002; 297:1-7.
99. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002; 76:5654-5666.
100. Alwan WH, Openshaw PJ. Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. Vaccine 1993; 11:431-437.
101. Openshaw PJ, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 2005; 18:541-555.
102. Murphy BR, Prince GA, Collins PL, Hildreth SW, Paradiso PR. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV). Vaccine 1991; 9:185-189.
103. Graham BS, Davis TH, Tang YW, Gruber WC. Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum. Pediatr Res 1993; 34:167-172.
104. Braciale TJ. Respiratory syncytial virus and T cells: Interplay between the virus and the host adaptive immune system. Proc Am Thorac Soc 2005; 2:141-146.
105. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991; 88:1026-1033.
106. Peebles RS,Jr, Graham BS. Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc 2005; 2:110-115.
107. + T cells. Clin Exp Immunol 1992; 88:527-536.
108. Tang YW, Graham BS. T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice. J Clin Invest 1997; 99:2183-2191.
109. Hussell T, Spender LC, Georgiou A, O'Garra A, Openshaw PJ. Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus. J Gen Virol 1996; 77 Pt 10:2447-2455.
110. Hussell T, Baldwin CJ, O'Garra A, Openshaw PJ. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur J Immunol. 1997; 27:3341-3349.
111. Buynak EB, Weibel RE, McLean A A, Hilleman MR. Live respiratory syncytial virus vaccine administered parenterally. Proc Soc Exp Biol Med 1978; 157:636-642.
112. Buynak EB, Weibel RE, Carlson AJ, McLean AA, Hilleman MR. Further investigations of live respiratory syncytial virus vaccine administered parenterally. Proc Soc Exp Biol Med 1979; 160:272-277.
113. Bembridge GP, Lopez JA, Bustos R, et al. Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge. J Virol 1999; 73:10086-10094.
114. Bembridge GP, Lopez JA, Cook R, Melero JA, Taylor G. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon. J Virol 1998; 72:4080-4087.
115. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990; 8:497-502.
116. Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 1992; 4:493-500.
117. van Woensel JB, Lutter R, Biezeveld MH, Dekker T, Nijhuis M, van Aalderen WM, Kuijpers TW. Effect of dexamethasone on tracheal viral load and interleukin-8 trachal concentration in children with respiratory syncytial virus infection. Pediatr Infect Dis J 2003; 22:721-726.
118. Chidgey SM, Broadley KJ. Respiratory syncytial virus infections: characteristics and treatment. J Pharm Pharmacol 2005; 57:1371-1381.
119. Mejias A, Chavez-Bueno S, Rios AM, et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrobial Agents Chemother 2005; 49:4700-4707.
120. Hall CB, Douglas RG, Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis 1980; 141:98-109.
121. Hall CB, Douglas RG. Modes of transmission of respiratory syncytial virus. J Pediatr 1981; 99:100-103.
122. Madge P, Paton JY, McColl JH, et al. Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus. Lancet 1992; 340:1079-1083.